Endovastec(SH:688016) Sou Hu Cai Jing·2026-02-09 11:34Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 98.3 yuan as of February 9, 2026, indicating a 0.33% rise. The trading volume was 9,421 lots, with a total transaction value of 92.59 million yuan [1]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%. However, the net profit attributable to shareholders decreased by 22.46% to 429 million yuan, and the net profit after deducting non-recurring gains and losses fell by 25.8% to 372 million yuan [1]. - In the third quarter of 2025, the company achieved a single-quarter main revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%. The single-quarter net profit attributable to shareholders was 114 million yuan, down 23.63%, while the net profit after deducting non-recurring gains and losses was 102 million yuan, a decrease of 11.84% [1]. - The company's debt ratio stands at 15.85%, with investment income of 11.6 million yuan and financial expenses of -7.86 million yuan. The gross profit margin is reported at 70.4% [1]. Market Sentiment - Over the last 90 days, three institutions have provided ratings for the stock, all of which are buy ratings [2]. - On February 9, 2026, the net outflow of main funds was 1.7167 million yuan, accounting for 1.85% of the total transaction value. The net outflow of speculative funds was 634,800 yuan, representing 0.69% of the total transaction value, while retail investors saw a net inflow of 2.3515 million yuan, making up 2.54% of the total transaction value [1].